Literature DB >> 20513161

Time for cooperation in health economics among the modelling community.

Renée J G Arnold1, Sean Ekins.   

Abstract

Mesh：

Year:  2010        PMID： 20513161     DOI： 10.2165/11537580-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  31 in total

Review 1.  An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.

Authors:  Anna O D'Souza; Michael J Smith; Lesley Ann Miller; Jan Kavookjian
Journal:  Chest       Date:  2006-06       Impact factor: 9.410

Review 2.  Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery.

Authors:  Moses Hohman; Kellan Gregory; Kelly Chibale; Peter J Smith; Sean Ekins; Barry Bunin
Journal:  Drug Discov Today       Date:  2009-02-11       Impact factor: 7.851

3.  A perspective of publicly accessible/open-access chemistry databases.

Authors:  Antony J Williams
Journal:  Drug Discov Today       Date:  2008-05-15       Impact factor: 7.851

Review 4.  Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery.

Authors:  Michael R Barnes; Lee Harland; Steven M Foord; Matthew D Hall; Ian Dix; Scott Thomas; Bryn I Williams-Jones; Cory R Brouwer
Journal:  Nat Rev Drug Discov       Date:  2009-07-17       Impact factor: 84.694

5.  The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level.

Authors:  N Kamel; C Compton; R Middelveld; T Higenbottam; S-E Dahlén
Journal:  Eur Respir J       Date:  2008-05       Impact factor: 16.671

6.  Competitive collaboration in the pharmaceutical and biotechnology industry.

Authors:  Alph Bingham; Sean Ekins
Journal:  Drug Discov Today       Date:  2009-10-14       Impact factor: 7.851

7.  Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.

Authors:  Andrew M Tonkin; Simon Eckermann; Harvey White; Denis Friedlander; Paul Glasziou; Paul Magnus; Adrienne Kirby; Sarah Mulray; Mary Denton; Michele Sallaberger; David Hunt; John Simes
Journal:  Am Heart J       Date:  2006-06       Impact factor: 4.749

8.  A multisite randomized trial of the effects of physician education and organizational change in chronic asthma care: cost-effectiveness analysis of the Pediatric Asthma Care Patient Outcomes Research Team II (PAC-PORT II).

Authors:  Sean D Sullivan; Todd A Lee; David K Blough; Jonathan A Finkelstein; Paula Lozano; Thomas S Inui; Anne L Fuhlbrigge; Vincent J Carey; Ed Wagner; Kevin B Weiss
Journal:  Arch Pediatr Adolesc Med       Date:  2005-05

Review 9.  Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.

Authors:  Thomas A Gaziano; Lionel H Opie; Milton C Weinstein
Journal:  Lancet       Date:  2006-08-19       Impact factor: 79.321

Review 10.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354
View more
  11 in total

1.  To model or not to model: lessons from two vaccinations.

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2011-06

2.  Ahead of Our Time: Collaboration in Modeling Then and Now.

Authors:  Renée J G Arnold; Sean Ekins
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

3.  Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling.

Authors:  Anthony J Hatswell; Fleur Chandler
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

Review 4.  Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics.

Authors:  Emma McManus; David Turner; Tracey Sach
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

Review 5.  Transparency in Decision Modelling: What, Why, Who and How?

Authors:  Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

6.  Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic non small cell lung cancer: An Indian study.

Authors:  Mangesh P Kamath; K C Lakshmaiah; K Govind Babu; D Loknatha; Linu A Jacob; Suresh Mc Babu
Journal:  Lung India       Date:  2016 Mar-Apr

7.  The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India.

Authors:  Govind Babu; Smitha Carol Saldanha; Lakshmaiah Kuntegowdanahalli Chinnagiriyappa; Linu Abraham Jacob; Suresh Babu Mallekavu; Loknatha Dasappa; Pretesh Rohan Kiran; Aparna Sreevatsa; Sandhya Appachu; Vineetha Unnikrishnan; Venugopal Arroju
Journal:  Chemother Res Pract       Date:  2016-01-27

8.  Model Registration: A Call to Action.

Authors:  Christopher James Sampson; Tim Wrightson
Journal:  Pharmacoecon Open       Date:  2017-06

Review 9.  Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis.

Authors:  Carlo Lombardi; Valerie Melli; Cristoforo Incorvaia; Erminia Ridolo
Journal:  Clin Mol Allergy       Date:  2017-03-07

10.  Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness.

Authors:  Linu A Jacob; S Aparna; K C Lakshmaiah; D Lokanatha; Govind Babu; Suresh Babu; Sandhya Appachu
Journal:  Adv Hematol       Date:  2015-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.